Table 4 Incidence rates and hazard ratios of vancomycin compared to all comparators and vancomycin compared to singular comparator, restricted to a cohort with at least 5 days of antibiotic treatment.

From: The comparative risk of acute kidney injury of vancomycin relative to other common antibiotics

 

N

Cases

Person timeb

Incidence rateb

95% CI

Crude HR

95% CI

Adjusted HRc

95% CI

Vancomycina

2959

14

12.41

1.13

0.67–1.91

    

Comparators

10,652

63

44.61

1.41

0.10–1.81

0.80

0.45–1.43

0.62

0.34–1.15

Cefazolin

6426

26

26.97

0.96

0.66–1.42

1.17

0.61–2.24

0.84

0.38–1.83

Linezolid

210

6

0.87

6.91

3.11–15.39

0.16

0.06–0.43

0.13

0.05–0.40

Piperacillin

2097

20

8.74

2.29

1.48–3.55

0.49

0.25–0.98

0.35

0.15–0.82

Cefepime

276

1

1.15

0.87

0.12–6.18

1.30

0.17–9.86

1.23

0.13–11.39

Meropenem

278

4

1.16

3.44

2.29–9.16

0.33

0.11–1.00

0.34

0.10–1.20

Ertapenem

1174

5

4.92

1.02

0.42–2.44

1.11

0.40–3.1

0.40

0.12–1.27

Daptomycin

191

1

0.80

1.25

0.18–8.90

0.90

0.12–6.85

0.68

0.08–5.81

  1. 95% CI 95% confidence interval, HR hazard ratio.
  2. aIndex group.
  3. bPer 10 person-years.
  4. cAdjusted for age, gender, medical history, co-medication, type of surgery, main diagnosis (not Included in model because of low cell count: vancomycin vs. piperacillin ,vancomycin vs. ertapenem, vancomycin vs. daptomycin, and vancomycin vs. cefepime).
Back to article page